search
Back to results

Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment (LANCELOT)

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Insulin Glargine (HOE901) [Lantus]
Glimepiride
human insulin [NPH]
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

30 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

  • Insulin-naïve type 2 diabetes mellitus
  • Type 2 diabetes mellitus diagnosed for at least 1 year
  • Treated with at least one OAD (Metformin [daily dose of at least 1000mg], Sulfonylurea, glinides or alpha-glucosidase inhibitor) at stable dose for at least 3 months.
  • HbA1c > or = 7.0% and < or = 10.5%
  • BMI < 40 kg/m²
  • Ability and willingness to perform plasma glucose monitoring using the sponsor-provided glucose meter and patient diary at home
  • Informed consent obtained in writing at enrolment into the study
  • Willingness and ability to comply with the study protocol

Exclusion criteria:

  • Treatment with GLP-1 agonists or with DPP-IV inhibitors in the 3 months prior to study entry
  • Treatment with TZD as monotherapy
  • Diabetes mellitus other than Type 2 (e.g. secondary to pancreatic disorders, drugs or chemical agents intake...)
  • Active proliferative retinopathy, as defined by a photocoagulation or vitrectomy occurrence in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgical treatment during the study (an optic fundus examination should have been performed within the 2 years prior to study entry)
  • Impaired renal function: serum creatinine > or =1.5 mg/dL (> or = 133µmol/L) or > or = 1.4 mg/dL (> or = 124 µmol/L) in men and women, respectively
  • History of sensitivity to the study drugs or to drugs with a similar chemical structure
  • Impaired hepatic function (ALT and/or AST > 3 x upper limit of normal range)
  • Pregnant or lactating women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method),
  • Treatment with systemic corticosteroids within the 3 months prior to study entry or likelihood of requiring treatments during the study which are not permitted.
  • Treatment with an investigational product in the 30 days prior to visit 1
  • Alcohol or drug abuse in the last year
  • Presence of any condition (medical, psychological, social or geographical), current or anticipated that the Investigator feels would compromise the patient's safety or limit the patient successful participation in the study (including night shift worker)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sites / Locations

  • Investigational Site Number 076-001
  • Investigational Site Number 076-006
  • Investigational Site Number 076-005
  • Investigational Site Number 076-007
  • Investigational Site Number 076-004
  • Investigational Site Number 076-003
  • Investigational Site Number 076-002
  • Investigational Site Number 203003
  • Investigational Site Number 203008
  • Investigational Site Number 203011
  • Investigational Site Number 203001
  • Investigational Site Number 203006
  • Investigational Site Number 203002
  • Investigational Site Number 203010
  • Investigational Site Number 203009
  • Investigational Site Number 203004
  • Investigational Site Number 203005
  • Investigational Site Number 203007
  • Investigational Site Number 818001
  • Investigational Site Number 250-002
  • Investigational Site Number 250-001
  • Investigational Site Number 250-005
  • Investigational Site Number 250-004
  • Investigational Site Number 250-003
  • Investigational Site Number 250-006
  • Investigational Site Number 380001
  • Investigational Site Number 410005
  • Investigational Site Number 410002
  • Investigational Site Number 410006
  • Investigational Site Number 410001
  • Investigational Site Number 410003
  • Investigational Site Number 410004
  • Investigational Site Number 414001
  • Investigational Site Number 484003
  • Investigational Site Number 484005
  • Investigational Site Number 484001
  • Investigational Site Number 484008
  • Investigational Site Number 484009
  • Investigational Site Number 484002
  • Investigational Site Number 528006
  • Investigational Site Number 528005
  • Investigational Site Number 528001
  • Investigational Site Number 528002
  • Investigational Site Number 528004
  • Investigational Site Number 528003
  • Investigational Site Number 616004
  • Investigational Site Number 616003
  • Investigational Site Number 616002
  • Investigational Site Number 616001
  • Investigational Site Number 642001
  • Investigational Site Number 642002
  • Investigational Site Number 642009
  • Investigational Site Number 642003
  • Investigational Site Number 642005
  • Investigational Site Number 642010
  • Investigational Site Number 642011
  • Investigational Site Number 642007
  • Investigational Site Number 642004
  • Investigational Site Number 642008
  • Investigational Site Number 642012
  • Investigational Site Number 643-001
  • Investigational Site Number 643-006
  • Investigational Site Number 643-005
  • Investigational Site Number 643-002
  • Investigational Site Number 643-003
  • Investigational Site Number 643-004
  • Investigational Site Number 643-007
  • Investigational Site Number 703005
  • Investigational Site Number 703003
  • Investigational Site Number 703007
  • Investigational Site Number 703004
  • Investigational Site Number 703006
  • Investigational Site Number 703002
  • Investigational Site Number 703008
  • Investigational Site Number 703001
  • Investigational Site Number 752004
  • Investigational Site Number 752002
  • Investigational Site Number 752003
  • Investigational Site Number 752001
  • Investigational Site Number 756001
  • Investigational Site Number 764004
  • Investigational Site Number 764001
  • Investigational Site Number 764002
  • Investigational Site Number 764003
  • Investigational Site Number 764006
  • Investigational Site Number 764005
  • Investigational Site Number 784-001

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

1

2

Arm Description

Before randomization (common with arm 2): 2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride After randomization: 36 weeks of study treatment phase: Insulin Glargine + OAD(s) at stable dose

Before randomization (common with arm 1): 2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride After randomization: 36 weeks of study treatment phase: NPH + OAD(s) at stable dose

Outcomes

Primary Outcome Measures

HbA1c

Secondary Outcome Measures

Self-monitored fasting plasma glucose (FPG)
8-points profiles
Episodes of hypoglycemia
Daily doses of insulin
Need of additional prandial insulin

Full Information

First Posted
July 27, 2009
Last Updated
August 20, 2012
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT00949442
Brief Title
Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment
Acronym
LANCELOT
Official Title
Superiority of Insulin Glargine Lantus vs. NPH: Treat to Normoglycemia Concept.Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-nave People With Type 2 Diabetes Mellitus Treated With at Least One OAD and Not Adequately Controlled
Study Type
Interventional

2. Study Status

Record Verification Date
August 2012
Overall Recruitment Status
Completed
Study Start Date
July 2009 (undefined)
Primary Completion Date
July 2012 (Actual)
Study Completion Date
July 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi

4. Oversight

5. Study Description

Brief Summary
Primary Objective: To demonstrate the superiority of insulin glargine over insulin NPH (Neutral Protamin Hagedornon) the change in HbA1c from baseline to the end of the treatment period. Secondary Objective: To compare between treatment groups: Plasma glucose (fasting, nocturnal) over time, Changes from baseline in HbA1c over time, Percentage of patients who reach the target of HbA1c <7 and <6.5, Use of prandial insulin as rescue medication at month 6, Incidence and rate of hypoglycemia (symptomatic diurnal and nocturnal, asymptomatic and severe), Daily dose of insulin, Change in body weight from baseline, Evolution of 8-point plasma-glucose (PG) profiles, Overall safety, Patient reported outcomes (treatment satisfaction).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
708 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Before randomization (common with arm 2): 2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride After randomization: 36 weeks of study treatment phase: Insulin Glargine + OAD(s) at stable dose
Arm Title
2
Arm Type
Active Comparator
Arm Description
Before randomization (common with arm 1): 2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride After randomization: 36 weeks of study treatment phase: NPH + OAD(s) at stable dose
Intervention Type
Drug
Intervention Name(s)
Insulin Glargine (HOE901) [Lantus]
Intervention Description
100 Units/ml solution for injection in a pre-filled pen SoloStar® (3 ml)
Intervention Type
Drug
Intervention Name(s)
Glimepiride
Intervention Description
tablets of 1 and 2 mg
Intervention Type
Drug
Intervention Name(s)
human insulin [NPH]
Intervention Description
100 IU/ml suspension for injection in a prefilled pen OptiSet® (3 ml)
Primary Outcome Measure Information:
Title
HbA1c
Time Frame
Recorded at baseline (week 0), week 12, week 24 and week 36
Secondary Outcome Measure Information:
Title
Self-monitored fasting plasma glucose (FPG)
Time Frame
Before baseline (week 0), weeks 12, 24 and 36
Title
8-points profiles
Time Frame
The week before baseline, at 12, 24 and 36 weeks
Title
Episodes of hypoglycemia
Time Frame
From the week -2 to the week 36
Title
Daily doses of insulin
Time Frame
At week 1, week 2, week 3, week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 20, week 24, week 28, week 32, week 36
Title
Need of additional prandial insulin
Time Frame
At week 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Insulin-naïve type 2 diabetes mellitus Type 2 diabetes mellitus diagnosed for at least 1 year Treated with at least one OAD (Metformin [daily dose of at least 1000mg], Sulfonylurea, glinides or alpha-glucosidase inhibitor) at stable dose for at least 3 months. HbA1c > or = 7.0% and < or = 10.5% BMI < 40 kg/m² Ability and willingness to perform plasma glucose monitoring using the sponsor-provided glucose meter and patient diary at home Informed consent obtained in writing at enrolment into the study Willingness and ability to comply with the study protocol Exclusion criteria: Treatment with GLP-1 agonists or with DPP-IV inhibitors in the 3 months prior to study entry Treatment with TZD as monotherapy Diabetes mellitus other than Type 2 (e.g. secondary to pancreatic disorders, drugs or chemical agents intake...) Active proliferative retinopathy, as defined by a photocoagulation or vitrectomy occurrence in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgical treatment during the study (an optic fundus examination should have been performed within the 2 years prior to study entry) Impaired renal function: serum creatinine > or =1.5 mg/dL (> or = 133µmol/L) or > or = 1.4 mg/dL (> or = 124 µmol/L) in men and women, respectively History of sensitivity to the study drugs or to drugs with a similar chemical structure Impaired hepatic function (ALT and/or AST > 3 x upper limit of normal range) Pregnant or lactating women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method), Treatment with systemic corticosteroids within the 3 months prior to study entry or likelihood of requiring treatments during the study which are not permitted. Treatment with an investigational product in the 30 days prior to visit 1 Alcohol or drug abuse in the last year Presence of any condition (medical, psychological, social or geographical), current or anticipated that the Investigator feels would compromise the patient's safety or limit the patient successful participation in the study (including night shift worker) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Valerie Pilorget, MD
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Investigational Site Number 076-001
City
Fortaleza
ZIP/Postal Code
60115-282
Country
Brazil
Facility Name
Investigational Site Number 076-006
City
Fortaleza
ZIP/Postal Code
60430-370
Country
Brazil
Facility Name
Investigational Site Number 076-005
City
Porto Alegre
ZIP/Postal Code
90035-170
Country
Brazil
Facility Name
Investigational Site Number 076-007
City
Rio de Janeiro
ZIP/Postal Code
202110340
Country
Brazil
Facility Name
Investigational Site Number 076-004
City
São Paulo
ZIP/Postal Code
01221-000
Country
Brazil
Facility Name
Investigational Site Number 076-003
City
São Paulo
ZIP/Postal Code
01244-030
Country
Brazil
Facility Name
Investigational Site Number 076-002
City
São Paulo
ZIP/Postal Code
04024-002
Country
Brazil
Facility Name
Investigational Site Number 203003
City
Beroun
ZIP/Postal Code
26601
Country
Czech Republic
Facility Name
Investigational Site Number 203008
City
Ceske Budejovice
ZIP/Postal Code
37001
Country
Czech Republic
Facility Name
Investigational Site Number 203011
City
Ceske Budejovice
ZIP/Postal Code
37007
Country
Czech Republic
Facility Name
Investigational Site Number 203001
City
Chrudim III
ZIP/Postal Code
53701
Country
Czech Republic
Facility Name
Investigational Site Number 203006
City
Hodonin
ZIP/Postal Code
69501
Country
Czech Republic
Facility Name
Investigational Site Number 203002
City
Hranice I - Mesto
ZIP/Postal Code
75301
Country
Czech Republic
Facility Name
Investigational Site Number 203010
City
Liberec
ZIP/Postal Code
46001
Country
Czech Republic
Facility Name
Investigational Site Number 203009
City
Moravsky Pisek
ZIP/Postal Code
39701
Country
Czech Republic
Facility Name
Investigational Site Number 203004
City
Praha 10
ZIP/Postal Code
10000
Country
Czech Republic
Facility Name
Investigational Site Number 203005
City
Praha 10
ZIP/Postal Code
10000
Country
Czech Republic
Facility Name
Investigational Site Number 203007
City
Praha 6
ZIP/Postal Code
16300
Country
Czech Republic
Facility Name
Investigational Site Number 818001
City
Menoufiya
Country
Egypt
Facility Name
Investigational Site Number 250-002
City
Aix En Provence
ZIP/Postal Code
13100
Country
France
Facility Name
Investigational Site Number 250-001
City
Antibes
ZIP/Postal Code
06600
Country
France
Facility Name
Investigational Site Number 250-005
City
Bordeaux
ZIP/Postal Code
33200
Country
France
Facility Name
Investigational Site Number 250-004
City
Jarny
ZIP/Postal Code
54800
Country
France
Facility Name
Investigational Site Number 250-003
City
NARBONNE Cedex
ZIP/Postal Code
11018
Country
France
Facility Name
Investigational Site Number 250-006
City
Strasbourg
ZIP/Postal Code
67000
Country
France
Facility Name
Investigational Site Number 380001
City
Perugia
ZIP/Postal Code
06156
Country
Italy
Facility Name
Investigational Site Number 410005
City
Daegu
Country
Korea, Republic of
Facility Name
Investigational Site Number 410002
City
Gyeonggi-Do
ZIP/Postal Code
420-717
Country
Korea, Republic of
Facility Name
Investigational Site Number 410006
City
Incheon
ZIP/Postal Code
400-711
Country
Korea, Republic of
Facility Name
Investigational Site Number 410001
City
Seoul
ZIP/Postal Code
137-701
Country
Korea, Republic of
Facility Name
Investigational Site Number 410003
City
Seoul
Country
Korea, Republic of
Facility Name
Investigational Site Number 410004
City
Seoul
Country
Korea, Republic of
Facility Name
Investigational Site Number 414001
City
Kuwait
Country
Kuwait
Facility Name
Investigational Site Number 484003
City
Guadalajara
ZIP/Postal Code
44150
Country
Mexico
Facility Name
Investigational Site Number 484005
City
Guadalajara
ZIP/Postal Code
44650
Country
Mexico
Facility Name
Investigational Site Number 484001
City
Monterrey
ZIP/Postal Code
64710
Country
Mexico
Facility Name
Investigational Site Number 484008
City
Pachuca
ZIP/Postal Code
042090
Country
Mexico
Facility Name
Investigational Site Number 484009
City
Pachuca
ZIP/Postal Code
42086
Country
Mexico
Facility Name
Investigational Site Number 484002
City
Puebla
ZIP/Postal Code
72190
Country
Mexico
Facility Name
Investigational Site Number 528006
City
Almelo
ZIP/Postal Code
7600SZ
Country
Netherlands
Facility Name
Investigational Site Number 528005
City
Apeldoorn
ZIP/Postal Code
7314 ET
Country
Netherlands
Facility Name
Investigational Site Number 528001
City
Beek
ZIP/Postal Code
6191JW
Country
Netherlands
Facility Name
Investigational Site Number 528002
City
Hoogeveen
ZIP/Postal Code
7909AA
Country
Netherlands
Facility Name
Investigational Site Number 528004
City
Hoogezand
ZIP/Postal Code
9603AE
Country
Netherlands
Facility Name
Investigational Site Number 528003
City
Rotterdam
ZIP/Postal Code
3053CD
Country
Netherlands
Facility Name
Investigational Site Number 616004
City
Gdansk
ZIP/Postal Code
80-211
Country
Poland
Facility Name
Investigational Site Number 616003
City
Kraków
ZIP/Postal Code
31-262
Country
Poland
Facility Name
Investigational Site Number 616002
City
Lublin
ZIP/Postal Code
20-954
Country
Poland
Facility Name
Investigational Site Number 616001
City
Zabrze
ZIP/Postal Code
41-800
Country
Poland
Facility Name
Investigational Site Number 642001
City
Bucharest
Country
Romania
Facility Name
Investigational Site Number 642002
City
Bucharest
Country
Romania
Facility Name
Investigational Site Number 642009
City
Cluj-Napoca
Country
Romania
Facility Name
Investigational Site Number 642003
City
Craiova
Country
Romania
Facility Name
Investigational Site Number 642005
City
Iasi
Country
Romania
Facility Name
Investigational Site Number 642010
City
Oradea
Country
Romania
Facility Name
Investigational Site Number 642011
City
Oradea
Country
Romania
Facility Name
Investigational Site Number 642007
City
Ploiesti
Country
Romania
Facility Name
Investigational Site Number 642004
City
Resita
Country
Romania
Facility Name
Investigational Site Number 642008
City
Targu-Mures
Country
Romania
Facility Name
Investigational Site Number 642012
City
Timisoara
Country
Romania
Facility Name
Investigational Site Number 643-001
City
Moscow
Country
Russian Federation
Facility Name
Investigational Site Number 643-006
City
Samara
Country
Russian Federation
Facility Name
Investigational Site Number 643-005
City
Saratov
Country
Russian Federation
Facility Name
Investigational Site Number 643-002
City
St-Petersburg
ZIP/Postal Code
195257
Country
Russian Federation
Facility Name
Investigational Site Number 643-003
City
St-Petersburg
Country
Russian Federation
Facility Name
Investigational Site Number 643-004
City
St-Ptetersburg
ZIP/Postal Code
194354
Country
Russian Federation
Facility Name
Investigational Site Number 643-007
City
Tyumen
ZIP/Postal Code
625046
Country
Russian Federation
Facility Name
Investigational Site Number 703005
City
Banská Bystrica
ZIP/Postal Code
97517
Country
Slovakia
Facility Name
Investigational Site Number 703003
City
Bratislava
ZIP/Postal Code
81102
Country
Slovakia
Facility Name
Investigational Site Number 703007
City
Bratislava
ZIP/Postal Code
82606
Country
Slovakia
Facility Name
Investigational Site Number 703004
City
Kosice
ZIP/Postal Code
04001
Country
Slovakia
Facility Name
Investigational Site Number 703006
City
Kosice
ZIP/Postal Code
04001
Country
Slovakia
Facility Name
Investigational Site Number 703002
City
Kosice
ZIP/Postal Code
04011
Country
Slovakia
Facility Name
Investigational Site Number 703008
City
Levice
ZIP/Postal Code
93401
Country
Slovakia
Facility Name
Investigational Site Number 703001
City
Martin
ZIP/Postal Code
03659
Country
Slovakia
Facility Name
Investigational Site Number 752004
City
Lund
ZIP/Postal Code
22361
Country
Sweden
Facility Name
Investigational Site Number 752002
City
Malmö
ZIP/Postal Code
21120
Country
Sweden
Facility Name
Investigational Site Number 752003
City
Skene
ZIP/Postal Code
51162
Country
Sweden
Facility Name
Investigational Site Number 752001
City
Stockholm
ZIP/Postal Code
17176
Country
Sweden
Facility Name
Investigational Site Number 756001
City
Geneve
ZIP/Postal Code
1205
Country
Switzerland
Facility Name
Investigational Site Number 764004
City
Bangkok
ZIP/Postal Code
10330
Country
Thailand
Facility Name
Investigational Site Number 764001
City
Bangkok
ZIP/Postal Code
10400
Country
Thailand
Facility Name
Investigational Site Number 764002
City
Chiangmai
ZIP/Postal Code
50002
Country
Thailand
Facility Name
Investigational Site Number 764003
City
Khon Kaen
ZIP/Postal Code
40002
Country
Thailand
Facility Name
Investigational Site Number 764006
City
Nakhonratchasima
ZIP/Postal Code
30000
Country
Thailand
Facility Name
Investigational Site Number 764005
City
Pathumthani
ZIP/Postal Code
12120
Country
Thailand
Facility Name
Investigational Site Number 784-001
City
Dubai
ZIP/Postal Code
4545
Country
United Arab Emirates

12. IPD Sharing Statement

Citations:
PubMed Identifier
33166419
Citation
Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.
Results Reference
derived
PubMed Identifier
24957785
Citation
Home PD, Bolli GB, Mathieu C, Deerochanawong C, Landgraf W, Candelas C, Pilorget V, Dain MP, Riddle MC. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes Obes Metab. 2015 Jan;17(1):15-22. doi: 10.1111/dom.12329. Epub 2014 Jul 12.
Results Reference
derived

Learn more about this trial

Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment

We'll reach out to this number within 24 hrs